INVA - テラバンス (Innoviva Inc.) テラバンス

 INVAのチャート


 INVAの企業情報

symbol INVA
会社名 Innoviva Inc (テラバンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 イノーバ(Innoviva Inc.)(旧名:Theravance Inc.)はバイオ医薬品の生産・商業化、及び財務管理に従事する。同社は、RELVAR / BREO ELLIPTA(フルチカゾンフロエート(FF)/ビランテロール(VI))及びANORO ELLIPTA(臭化ウムクリジニウム/ビランテロール(UMEC / VI))を含むGlaxo Group Limited (GSK) と提携した呼吸器資産に焦点を当てる。GSKとの長期契約ベータ2アゴニスト(LABA)コラボレーション契約および戦略的アライアンス契約に基づき、同社はリルバール/ブリオ・エルピタの販売においてGSKから年間ロイヤルティを受け取る資格がある。ANORO ELLIPTA等のLABAコラボレーションのLABAと組み合わされた他の製品については、ロイヤルティは上向きで6.5%から10%の範囲である。RELVAR / BREOは、LABA(VI)と吸入コルチコステロイド(ICS)、FFで構成される一日一回の組み合わせ吸入呼吸器薬である。ANORO ELLIPTAは、長時間作用型ムスカリンアンタゴニスト(LAMA)、臭化ウムクリジニウム(UMEC)、LABAを組み合わせた1日1回の薬である。  テラバンスは米国のバイオ医薬品メ―カ―。主に呼吸器疾患、細菌感染、中枢神経系疼痛などの治療分野における小分子薬の発見・開発・製品化に従事。主な製品候補は、「RELVAR」、「BREO」、「ELLIPTA」、「ANORO」、「MABA」。それぞれがグラクソ・スミスクラインとの長時間作用型ムスカリン拮抗薬プログラムと提携。   Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
本社所在地 2000 Sierra Point Parkway Suite 500 Brisbane CA 94005 USA
代表者氏名 William H. Waltrip ウィリアムH.ウォルトリット
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-238-9600
設立年月日 35370
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 12人
url www.inva.com
nasdaq_url https://www.nasdaq.com/symbol/inva
adr_tso
EBITDA EBITDA(百万ドル) 223.72800
終値(lastsale) 15.36
時価総額(marketcap) 1559158963.2
時価総額 時価総額(百万ドル) 1591.641
売上高 売上高(百万ドル) 237.62900
企業価値(EV) 企業価値(EV)(百万ドル) 1970.626
当期純利益 当期純利益(百万ドル) 166.35900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Innoviva Inc revenues increased 21% to $119.5M. Net income increased 62% to $84.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest expense decrease of 43% to $14.1M (expense) General and administrative decrease of 41% to $9.8M (expense) Stock Based Comp.

 INVAのテクニカル分析


 INVAのニュース

   Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates  2020/07/31 19:56:58 Benzinga
July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP ) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT ) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ ) drug to treat excessive daytime sleepiness were among those which successfully cleared the FDA hurdle. A few others, including Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX ), are forced to wait. The regulatory agency handed down a complete response letter for Verrica's viral skin infection treatment, while Eagle Pharma's PDUFA date for its exertional heat stroke drug was postponed until Aug. 8 due to FDA's reallocation of resources due to COVID-19. Four new molecular entities, or NMEs, were approved in July, taking the total number of NME approvals for the year to 29. Here are the key PDUFA dates scheduled for August. GSK Seeks To Expand Use Of Triple Combo Drug To Asthma Company: GlaxoSmithKline plc (NYSE: GSK ) Type of Application: sNDA Candidate: Trelegy Elypta Indication: asthma Date: Aug. 2 (estimated based on the 10-review period from the regulatory application filing date of Oct. 2) Trelegy Elypta is a single inhaled triple therapy consisting of fluticasone furoate/umeclidinium/vilanterol) and has already been approved for chronic obstructive pulmonary disease.
   Innoviva Reports Second Quarter 2020 Financial Results  2020/07/29 20:05:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2020. Gross royalty revenues of $72.4 million from Glaxo Group Limited (“GSK”) for the second quarter of 2020 included royalties of $45.6 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $11.2 million from global net sales of ANORO® ELLIPTA® and royalties of $15.6 million from global net sales of TRELEGY® ELLIPTA®.1 Changes
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Innoviva (INVA) Stock Moves -0.77%: What You Should Know  2020/06/09 21:50:06 Zacks Investment Research
Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.
   Innoviva (INVA) Gains But Lags Market: What You Should Know  2020/06/03 21:50:05 Zacks Investment Research
Innoviva (INVA) closed the most recent trading day at $13.92, moving +0.43% from the previous trading session.
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Innoviva (INVA) Stock Moves -0.77%: What You Should Know  2020/06/09 21:50:06 Zacks Investment Research
Innoviva (INVA) closed at $14.13 in the latest trading session, marking a -0.77% move from the prior day.
   Innoviva (INVA) Gains But Lags Market: What You Should Know  2020/06/03 21:50:05 Zacks Investment Research
Innoviva (INVA) closed the most recent trading day at $13.92, moving +0.43% from the previous trading session.
   Innoviva Names Pavel Raifeld as Chief Executive Officer  2020/05/21 20:05:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective May 20, 2020. Mr. Raifeld is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of his career on the creation of significant shareholder value. Mr. Raifeld replaces Geoff Hulme, who served as the Company’s principal executive officer since May 2018.
   Are Investors Undervaluing Innoviva (INVA) Right Now?  2020/05/21 15:50:14 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
   Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?  2020/05/01 15:30:17 Zacks Investment Research
Is (INVA) Outperforming Other Medical Stocks This Year?
   Innoviva Reports First Quarter 2020 Financial Results  2020/04/29 20:05:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ:INVA) ("Innoviva," or "the Company") today reported financial results for the first quarter ended March 31, 2020. Gross royalty revenues of $82.1 million from Glaxo Group Limited (“GSK”) for the first quarter of 2020 included royalties of $56.1 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $9.9 million from global net sales of ANORO® ELLIPTA® and $16.1 million from global net sales of TRELEGY® ELLIPTA®.[1] Total
   Innoviva Announces Change of Location of Annual Meeting of Stockholders to Be Held on April 24, 2020  2020/03/31 20:05:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) announced today that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual meeting format only. As previously announced, the annual meeting will be held on Friday, April 24, 2020 at 10:00 a.m. Eastern Time. To be admitted to the annual meeting at www.virtualshareholdermeeting.com/
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Innoviva Reports Fourth Quarter 2019 Financial Results  2020/02/05 21:05:00 Business Wire
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the fourth quarter ended December 31, 2019. Gross royalty revenues of $79.4 million from Glaxo Group Limited (“GSK”) for the fourth quarter of 2019 included royalties of $53.1 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $11.9 million from global net sales of ANORO® ELLIPTA® and $14.4 million from global net sales of TRELEGY® ELLIPTA®.1 Total operating e

 関連キーワード  (医薬品 米国株 テラバンス INVA Innoviva Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)